Don't bet against Vertex Pharmaceuticals in cystic fibrosis.

Vertex Pharmaceuticals has raced ahead of the market, while analysts continue to give the stock a decidedly optimistic outlook.

Businesses with strong free cash flow tend to be more adaptable and resilient. Some of these companies shine bright by using their cash wisely to strengthen their market positions.

On July 29, AbCellera Biologics Inc. (NASDAQ:ABCL) and Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) announced a strategic collaboration to research, develop, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases. Under the agreement, AbCellera will leverage its proprietary TCE platform to lead discovery, while Vertex will fund all research and development and retain commercialization rights. In return, […]

Vertex Pharmaceuticals stock has delivered a strong 5 year return, yet current checks suggest the market now prices it roughly in line with its fundamentals rather than as an obvious bargain. Recent news around pipeline catalysts and competitive threats keeps the focus on whether that pricing still leaves enough room for missteps. Over the past 5 years, Vertex Pharmaceuticals has returned 158.2%, which puts recent valuation questions in the context of a stock that has already rewarded long...

The drugmaker should significantly mitigate its most important risk as it develops new products.

Vertex Pharmaceuticals (VRTX) has drawn fresh attention after reporting second quarter 2026 results, raising full year revenue guidance to US$13.1b to US$13.2b, and completing a US$1.42b share repurchase program. See our latest analysis for Vertex Pharmaceuticals. The latest updates on guidance and buybacks come after a solid run in Vertex Pharmaceuticals' stock, with a 90 day share price return of 18.19% and a 1 year total shareholder return of 31.48%. This suggests momentum has been...

Picture three students turning in exams on the same day, covering the same material. Two walk away with high marks. The third has been raising his grades all semester, yet still gets flagged for summer school. That is roughly the dynamic inside the BofA research note on biotech I received on the ...

A California biotech just raised $350 million promising to out-perform opioids without the addiction risk, and its auditors were still warning about survival just months ago. Here is what the science and the filings actually show.

Vertex Pharmaceuticals (VRTX) has multiple potential catalysts coming from its portfolio that provid

Cystic fibrosis investors came to learn a harsh lesson on August 10 about how concentrated a market can be: Sionna Therapeutics, Inc. (NASDAQ:SION) shares fell more than 90% following a key trial failure, while Vertex Pharmaceuticals (NASDAQ:VRTX), the company whose drug dominance Sionna was attempting to challenge, surged to new highs. The Pipeline Flop Sionna […]

Vertex Pharmaceuticals’ second quarter reflected strong commercial momentum, with management highlighting the performance of its cystic fibrosis (CF) portfolio and accelerating uptake of newer products like CASGEVY and JOURNAVX. CEO Reshma Kewalramani attributed revenue growth to “the strength of our cystic fibrosis portfolio and the growing contributions from our newer products,” while also emphasizing progress in regulatory and clinical milestones. Management specifically noted that ALYFTREK a